Sun. May 19th, 2024

Red and White joined arrow


Shares of Viking Therapeutics (NASDAQ:VKTX) have surged in the last 12 months, driven by the success of its obesity candidate, the subcutaneously administered VK2735. VK2735’s efficacy, safety and tolerability data to date look very competitive, even when compared to the so-calledLLY

Source link

By admin